The company carried out research on new Textray chest x-ray, which showed high rates of agreement between the algorithm and human radiologist experts.

The chest x-ray AI analytics product has been trained using around two million images for the identification of 40 different common clinical findings, enabling to establish a new bar for AI research in medical imaging.

Zebra Medical Vision co-founder and CEO Elad Benjamin said: “I’m extremely proud of our team here at Zebra Medical Vision, that is pushing to develop and release next generation AI products with the commitment to make them affordable to the global market.”

Zebra Medical has also secured $30m series C financing, taking the firm’s total investment to $50m.

The funding round was led by aMoon Ventures, while the participants included strategic healthcare investors such as Aurum, Johnson & Johnson Innovation JJDC and Intermountain Healthcare, as well as AI scientists Professor Fei Fei Lee and Richard Socher.

In addition, the existing investors such as Khosla Ventures, NVIDIA, Marc Benioff, OurCrowd and Dolby Ventures participated in the current financing round.

Aurum Ventures founder and owner Morris Kahn said: “I am a big believer in AI based healthcare solutions and Zebra Medical Vision’s technologies will play a major role in improving the capacity and quality of treatment for patients all over the world.”

In May this year, Zebra Medical Vision secured CE mark approval for its new algorithm, which is part of the firm’s Deep Learning Imaging Analytics platform.

The new algorithm holds capacity to detect suspected malignant lesions in mammography scans.

Zebra Medical also developed algorithms that can automatically detect brain bleeds, vertebral fractures, coronary artery disease and osteoporosis.

Based in Kibbutz Shefayim of Israel, Zebra Medical uses deep learning to create and provide next generation products and services to the healthcare industry.